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ABSTRACT Satellite cells are the main source of
myogenic progenitors in postnatal skeletal muscle, but
their use in cell therapy for muscle disorders is limited
because these cells cannot be delivered through circu-
lation and they are rapidly exhausted in severe myopa-
thies. The search for alternative donor cells is ongoing,
but none of the candidates so far show all the features
required for successful colonization and repair of
diseased muscle. In this study, we show that bisperox-
ovanadium, a phospho-tyrosine phosphatase inhibitor,
induces myogenic cells to acquire a gene expression
profile and a differentiation potential consistent with
the phenotype of a circulating precursors, while main-
taining their myogenic potential. These effects are
mediated, at least in part, by NF-B activation through
the Tyr42-IB- phosphorylation, as shown by the
expression of the dominant negative mutant form of
the p50 NF-B subunit. Moreover, when bisperoxova-
nadium-treated cells are injected into the femoral ar-
tery of -sarcoglican null dystrophic mice, they are able
to circulate and to reach muscle tissue; importantly,
they contribute to muscle regeneration, as shown by the
expression of -sarcoglican in some fibers. Our obser-
vations indicate that bisperoxovanadium, or similar
compounds, may prove very valuable to obtain and to
expand, from committed cells, multipotent cell popu-
lations suitable for gene-cell therapy applications and
may help to understand the molecular basis of genome
reprogramming and “stem-ness.”—Castaldi, L., Serra,
C., Moretti, F., Messina, G., Paoletti, R., Sampaolesi,
M., Torgovnick, A., Baiocchi, M., Padula, F., Pisaniello
A., Molinaro, M., Cossu, G., Levrero, M., Bouche´, M.
Bisperoxovanadium, a phospho-tyrosine phosphatase
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Muscle regeneration in case of injury or muscular
diseases is guaranteed by the activation and differentia-
tion of satellite cells (SCs), the myogenic precursors
located beneath the basal lamina of individual myofibers.
SCs are characterized by the expression of the transcrip-
tion factors Pax7, Msx1, and, in a subset of muscles, Pax3,
of the cell surface molecules CD34, M-cadherin, and
c-met and of structural proteins such as desmin (for a
review see ref. 1). SCs are both able to self-renew to
maintain their own pool and, upon activation, to give rise
to a large number of daughter myoblasts. The use of
muscle SCs in cell-mediated gene therapy approaches to
correct genetic diseases, such as muscular dystrophies, is,
however, limited by their rapid loss after transplantation
(2). Moreover, SCs cannot cross the vessel wall, and thus
systemic delivery is not possible (3). Recently, freshly
isolated and homogeneous SCs have been shown to
contribute to both muscle repair and SCs compartment
repopulation, when grafted into mdx mice (4). However,
SCs expansion in culture before the engraftment greatly
reduces the regenerative capacity, thus limiting their use
in vivo. Although SCs are the main cellular source for
muscle regeneration (5), other cell populations, includ-
ing bone marrow-derived cells, bone marrow or muscle
derived side population (SP), mesangioblasts, or other
mesodermal-derived progenitors, can activate a myogenic
program (3, 6–9). In most cases, the number of these cells
that can be isolated from adult tissues is limited, in vitro
expansion is problematic, and their actual myogenic
potential is variable and possibly due to fusion, rather
than transdifferentiation (10, 11).
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Committed and even terminally differentiated cells,
as well as established cell lines, can dedifferentiate
and/or transdifferentiate upon ectopic expression of
specific genes. Myoblasts can be converted into physio-
logically active neurons through the activation of neu-
ronal differentiation genes (12). Surprisingly, termi-
nally differentiated myotubes can be induced to
partially dedifferentiate by the expression of viral on-
coproteins or of the homeobox protein msx1 (13, 14).
More recently, bone marrow stromal cells have been
shown to differentiate, upon ectopic expression of
NICD, into various cell types in vivo (15). Thus, repro-
gramming of gene expression in committed cells might
be exploited to develop innovative cell therapy strate-
gies. Ideally, the differentiation program should be
inhibited in a reversible manner to allow the cells to
redifferentiate when placed in the right microenviron-
ment. Pharmacological manipulation of signaling path-
ways and downstream transcription factors known to
inhibit myogenic differentiation could be a reasonable
alternative to the ectopic expression of a given gene
and would ensure the reversibility by simple removal of
the drug.
NF-B and AP1 transcriptional activities are known to
be rapidly down-regulated when muscle cells are in-
duced to differentiate (16), whereas forced NF-B
and/or AP1 activity inhibits myogenesis through the
regulation of cyclin D1 and/or of MyoD and myogenin
(17, 18). In this study, we tested the ability of bisperox-
ovanadium (BpV), a protein tyrosine phosphatase
(PTP) inhibitor known to activate both NF-B and AP1
signaling, to generate, from committed myoblasts, mul-
tipotent cell populations suitable for gene-cell therapy
applications.
MATERIALS AND METHODS
Cell cultures
Muscle cell cultures
C2C12 cells, a mouse satellite cell-derived cell line (19), were
grown in growing medium (GM) [Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10% fetal calf
serum (FCS)]; to induce differentiation, the medium was
replaced with differentiation medium (DM) [DMEM supple-
mented with 2% horse serum (HS), as described in ref. 20].
Primary mouse satellite cells (MSC) were prepared from 1–2
wk postnatal mouse limbs as described previously (21). The
cells were grown in DMEM supplemented with 20% HS and
5% chick embryo extract (EE). To induce differentiation, the
cells were shifted to DMEM supplemented with 5% HS and
1.25% EE for 3–5 days. In both cases, BpV (10 M) was added
upon shifting into DM.
Hematopoietic colony assay
C2C12 cells (103 cells/35mm dish) were cultured in a meth-
ylcellulose medium for colony assay of murine cells (Metho-
Cult, Stem Cell Technologies, Inc., Vancouver, Canada) and
then cultured for 4–5 days.
Coculture with cardiomyocytes
Neonatal cardiac myocytes were prepared as described previ-
ously (22); 104 GFP-C2C12 cells/35mm tissue culture dish
were seeded on the cardiomyocytes monolayer and cultured
for additional 5 days in DM.
Cell transfections and reporter gene assays
Transfection of C2C12 cells and luciferase reporter assays
were performed as described previously (20). NF-BLuc and
AP1Luc were purchased from Promega (Madison, WI, USA).
The pRSV-p65 expression vector was previously described
(23); the p50SP (NF-Bp50 dominant negative) was pro-
vided by Dr. P. M. Khavari (24). Previous studies demon-
strated that exogenous expression of p50SP resulted in
inhibition of transcriptional inducibility of the target genes by
NF-B (25).
Cell fractionation, immunoprecipitation,
and immunoblotting
For cell fractionation, C2C12 cells were collected, sus-
pended in lysis buffer (20 mM HEPES, pH 7.5, 10 mM
NaCl, phosphatase and protease inhibitors), and incubated
15 min. on ice. Nuclear fractions were obtained by centrif-
ugation. Protein concentrations of both cytoplasmic and
nuclear fractions were equalized, and SDS sample buffer
was added to 1 final concentration. Immunoprecipitation
and immunoblotting were performed as previously de-
scribed (26). The following antibodies were used: anti-p65
(Transduction Laboratories, San Jose, CA, USA), anti-Ph-
Tyr (Cell Signaling, Danvers, MA, USA), anti-IB, anti-Ph-
Ser-32 IB, antic-jun, anti-Ph-Ser-63 c-jun, and anti-p50
(clone C-19; all from Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
RNA preparation and reverse transcriptase-polymerase
chain reaction (RT-PCR) analysis
Total RNA extraction and cDNA synthesis were done as
described previously (21). The following PCR protocol was
applied for all primer sets: 95°C for 5 min, followed by 30
cycles of PCR (1 min at 95°C, 1 min at annealing tempera-
ture, 2 min at 72°C), and a final 7 min extension step at 72°C.
PCR products were separated on 1% agarose gel containing
ethidium bromide. The following primers were used for PCR
amplifications: -actin: fw ATGCCTCTGGTCGTACCACAG-
GCATTG, rev TTGCTGATCCACATCTGCTGGAAGGTG (ex-
pected band 649 bp); MyoD: fw GAGCAAAGTGAATGAGGC-
CTT, rev CACTGTAGTAGGCGGTGTCGT (expected band
330 bp); myogenin: fw AGTGAATGCAACTCCCACAG, rev
TCAGAAGAGGATGCTCTCTGC (expected band 450 bp);
Myf-5: fw TGCCATCCGCTACATTGAGAG, rev CCGGGG-
TAGCAGGCTGTGAGTTG (expected band 370 bp); Pax-3: fw
AGGAGGCGGATCTAGAAAGGAAG, rev TGTGGAATA-
GACGTGGGCTGGTA (expected band 450 bp); Pax-7: fw
TACCAGGAGACCGGGTCCATC, rev TCCGAACTTGAT-
TCTGAGC (expected band 236 bp); alternatively, a different
pair of primers was used for Pax 7 (which gave the same
results): fw CTCCCGTCAGCTCCGTGTTTCTCA, rev AT-
GTCCGGGTAGTGGGTCCTCTCG (expected band 500 bp);
PCNA: fw TCCTTGGTACAGCTTACT, rev TGCTAAGGT-
GTCTGCATT (expected band 165 bp); cyclin D1: fw GT-
GCCATCCATGCGGAA, rev GGATGGTCTGCTTGTTCTCA
(expected band 362 bp); Sca-1: fw GATTCTCAAACAAG-
GAAAGTA, rev GACTGAGCTCAGGCTGAACAG (expected
band 200 bp); c-Met: fw GAATGTCGTCCTACACGGCC, rev
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CACTACACAGTCAGGACACTGC (expected band 370 bp);
ALP: fw GCCCTCTCCAAGACATATA, rev CCATGAT-
CACGTCGATATCC (expected band 372 bp); osteocalcin: fw
AAGCAGGAGGGCAATAAGGT, rev AGCTGCTGTGACATC-
CATAC (expected band 292 bp); collagen 1A2: fw
GCAATCGGGATCAGTACGAA, rev CTTTCACGCCTTT-
GAAGCCA (expected band 484 bp); Cbfa 1: fw CCGCAC-
GACAACCGCACCAT, rev CGCTCCGGCCCACAAATCTC
(expected band 289 bp); MITF: fw ACCATCAGCAACTCCT-
GTCC, rev TCTTGCTTGATGATCCGATTC (expected band
450 bp); MMP9: fw CCTGTGTGTTCCCGTTCATCT, rev
CGCTGGAATGATCTAAGCCCA (expected band 380 bp);
IL3-R: fw TACCACATCCAGATGGAACC, rev TACCACATC-
CAGATGGAACC (expected band 428 bp); GM-CSFR: fw
AACGTGACTGACAGGAAGG, rev TGTGTGTGCTGGCT-
GTTAAGG (expected band 454 bp); Bpcr 1: fw CCATAG-
CCACAGGCCAAAGT, rev GGGCCACATGATTCTTCCAC
(expected band 330 bp); MDR1a: fw CCCATCATTGCGAT-
AGCTGG, rev TCCAACATATTCGGCTTTAGGC (expected
band 500 bp); MDR1b: fw TGCTTATGGATCCCAGAGTGAC,
rev TTGGTGAGGATCTCTCCGGCT (expected band 430
bp); SG: fw TCGAGACAGTTTTGACACCACTAGA, rev
GCTGCGCACCAGGAACTC. Quantitative real-time PCR was
carried out as described previously (27).
Histochemical and immunofluorescence analyses
Alkaline phosphatase (ALP) or tartrate-resistant acid phos-
phatase (TRAP) activities were assayed on fixed cells using
the ALP substrate or the leukocyte acid phosphatase re-
agent, respectively (both from Sigma-Aldrich, St. Louis,
MO, USA), according to manufacturer’s instructions. Im-
munofluorescence on cells or muscle cryosections was
performed as described previously (20). The following
primary antibodies were used: anti-sarcomeric myosin
heavy chains MF20 (21); anti-cardiac troponin I (cTnI;
Covance, Princeton, NJ, USA); anti-laminin (Sigma-Al-
drich); anti-c-kit (BD Biosciences, San Jose, CA, USA),
anti-MyoD (Dako, Glostrup, Denmark); anti-sarcoglican
(-SG; Novocastra, Newcastle upon Tyne, UK). Fluoro-
chrome-labeled secondary antibodies (Sigma) and Hoechst
(Fluka, Buchs, Switzerland) for nuclear staining were then
used. Samples were examined in a Zeiss Axioskop 2 Plus
fluorescence microscope, equipped with a CCD camera.
Flow cytometry analysis
Cells (106) were incubated on ice with 1 g of the
appropriate fluorochrome-labeled antibody and analyzed
with a FacsStar Plus cytofluorimeter. The following anti-
bodies were used: anti-Sca-1, -CD45, -c-kit, -CD34, -CD11b,
-Gr-1, -Ter-119, and -Mac-3 (BD Biosciences). Nonspecific
fluorescent emission was determined with the specific
labeled isotype. For cell cycle analysis, cells were stained
with propidium iodide.
Intra-arterial transplantation
BpV-treated or untreated GFP-C2C12 cells (5105) were
injected into the femoral artery of 2-mo-old mice, as
described previously (3, 9); -SG null mice (SG/) were
kindly provided by Dr K. P. Campbell (28). Mice were
euthanized at 3, 5, 7, or 21 days after injection; single
muscles were dissected and either processed for cryosec-
tions or used for RNA preparation. All procedures were
conducted in conformity with the institutional guidelines
that are in compliance with national and international laws
and policies.
Statistical analysis
Statistical analysis was conducted using a t test. The criterion
for statistical significance was *P  0.05.
RESULTS
BpV treatment reversibly inhibits myogenic
differentiation
We first analyzed the effect of BpV treatment on
myogenic differentiation. Subclonfluent growing
C2C12 cells were placed in DM, with or without 10
M BpV. Within 4 –5 h of treatment, BpV-treated
C2C12 cells acquired a round shaped morphology;
moreover, many of the cells detached from the dish,
without showing any features of degeneration or
apoptosis (Fig. 1A). BpV-treated primary MSC, which
are already round shaped, detached from the dish to
a similar extent (data not shown). Long-term (48 –72
h) exposure to BpV inhibited the formation of
C2C12 and MSC multinucleated myotubes (Fig. 1A
and data not shown). The inhibition of myogenic
differentiation was paralleled by a sharp down-regu-
lation of the muscle regulatory factors (MRFs) tran-
scripts (MyoD, myf5, and myogenin) in both C2C12
cells and MSCs; it is noteworthy that to achieve an
equivalent MRF down-regulation as in MSCs, C2C12
cells needed to be exposed to BpV for 48 h, suggest-
ing that the inhibition of myogenic differentiation
occurs with different kinetics in the two cell popula-
tions (Fig. 1B).
To verify whether BpV-treated cells maintained
their myogenic potential, C2C12 cells and MSCs
were transferred in DM with or without 10 M BpV;
after 24 h, the medium was replaced with fresh
DM, cultured for additional 3 days in the absence of
BpV, and analyzed for myosin expression by immu-
nofluorescence. Parallel cultures were maintained
in DM containing BpV. As shown in Fig. 1C, while
no myosin-positive cells were found when the cells
were exposed to BpV continuously, both pretreated
C2C12 cells and MSCs still differentiated into
multinucleated myosin-positive myotubes, upon BpV
removal, with a fusion rate only slightly lower than
untreated cells.
BpV treatment induces cell cycle progression
Permanent withdrawal from the cell cycle is a prereq-
uisite for myogenic differentiation. To verify whether
the BpV-dependent blockade of the myogenic program
was associated to changes in the proliferative capacity of
myogenic cells, cell cycle was monitored by FACS
analysis in BpV-treated, untreated, and proliferating
C2C12 cells, cultured for different periods of time (Fig.
2A–C). C2C12 cells cultured in BpV-containing DM
displayed both a slower decrease in the percentage of
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cells in the S phase and a slower accumulation in the
percentage of cells in the G1 phase, as compared to
untreated cells, even when cultured in GM. Accord-
ingly, RT-PCR analysis demonstrated the up-regulation
of both cyclin D1, a marker of the G1/S phase transi-
tion, and PCNA, a marker of the S phase, in BpV-
treated C2C12 cells and MSC, as compared to un-
treated cells (Fig. 2, D).
Figure 1. Effect of BpV on muscle cell differentiation. A) Phase contrast micrographs of C2C12 cells cultured in the absence (a,
c) or in the presence (b, d) of 10 M BpV for 12 (a, b) or 72 h (c, d). B) RT-PCR analysis for expression of indicated MRFs in
C2C12 cells or MSC cultured in DM for 24 h in the absence (lane 1) or in the presence (lane 2) of 10 M BpV. RT-PCR in C2C12
cells cultured 48 h in the presence of 10 M BpV is also shown (lane 3). C) Reversibility of BpV effects. Immunofluorescence
analysis of myosin expression in C2C12 cells (a–d) and MSCs (e–h). a, e) C2C12 cells and MSC, respectively, cultured for 3 days
in DM. b, f) C2C12 cells and MSC, respectively, cultured in BpV-containing DM for 3 days. c, g) C2C12 cells and MSC,
respectively, cultured in BpV-containing DM for 24 h and then for additional 3 days on BpV removal. Fusion rate in cells treated
as in e and g is shown in d and h, as percentage of nuclei in myosin-positive cells over total number of nuclei in each conditions,
assuming fusion rate in untreated cells as 100% (d, C2C12 cells, h, MSCs). Bars 	 50 m.
Figure 2. Effect of BpV on cell proliferation. Percentage of C2C12 cells in G1 (A), S (B), or G2 (C) phase, as determined by FACS
analysis of cell cycle. Cells were cultured either in DM with or without BpV, either in GM, for indicated period of time. By
statistical analysis, significance was found comparing cells cultured in DM 
 BpV vs. those cultured in DM (***P0.0001). D,
C)	 RT-PCR analysis of expression of PCNA and cyclin D1 in C2C12 cells and MSCs treated or not with BpV for 24 h. expression
level of -actin was analyzed to normalize reactions.
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BpV imposes a phenotype of muscle precursor cells
to C2C12 and MSC
To characterize the phenotype acquired by C2C12
cells and MSCs on BpV treatment, we first analyzed
by RT-PCR the expression of markers defining the
muscle derived stem cells (MDSC; ref. 7). In contrast
to MRFs, the expression of which was down-regulated
in response to 24 – 48 h BpV treatment (Fig. 1A), the
expression of the MDSC markers Sca-1, Pax-3, and
c-met were all sustained both in C2C12 cells and
MSCs (Fig. 3A). Accordingly, the expression of the
satellite cell marker Pax 7, which is known to be
down-regulated when the cells are induced to differ-
entiate, was also maintained by BpV treatment in
both C2C12 and MSCs; however, longer exposure (48
h) led to its down-regulation, in line with the block of
the myogenic program (Fig. 3A). A characteristic
shared by most MDSCs is the ability, upon Hoechst
33342 staining, to locate as an SP in the FACS profile,
due to the exclusion of the dye through the activity of
members of the ABC transporter superfamily [the
multidrug resistance-1 (MDR1) and the breast cancer
resistance protein (BCRP1)]. As shown in Fig. 3B,
untreated C2C12 cells expressed BCRP1, and its
expression was not modified by BpV treatment; by
contrast, the expression of MDR1a and b, undetect-
able in untreated cells, was highly up-regulated upon
BpV treatment. Untreated MSCs expressed MDR1b
at levels that were not further increased by BpV
treatment, whereas the expression of MDR1a and
BCRP1, undetectable in untreated cells, was highly
up-regulated in BpV-treated MSCs. Thus, BpV-
treated myogenic cells display a complete set of the
ABC transporters. Accordingly, SP subpopulation
increased in both C2C12 cells and MSCs exposed to
BpV, as shown by Hoechst 33342 staining (Fig. 3B).
The very low percentage (0.02%) of the total C2C12
cell population located in the SP fraction increased
4- to 5-fold (0.11%) in response to BpV treatment. As
expected, a higher percentage (0.11%) of untreated
MSCs showed the SP phenotype and BpV treatment
resulted in a 2-fold increase in the percentage of SP
population (0.21%).
BpV induces stem and hematopoietic markers in
C2C12 and primary SCs
We next analyzed untreated and BpV-treated C2C12
cells for the expression of stem and hematopoietic
surface markers by FACS (Fig. 3C). We found that,
upon 24 h BpV treatment, the stem cell markers
Sca-1 and c-kit, already detectable in untreated cells,
were significantly up-regulated; the expression of
CD34, a marker of hematopoietic stem cells as well as
of quiescent SCs, was further increased; the hemato-
poietic marker CD45 was strongly up-regulated,
whereas CD11b, a monocyte/macrophage marker,
displayed a modest up-regulation. Finally, the expres-
sions of Mac-3, Gr-1, and Ter119, markers of macro-
phages, granulocytes, and erythrocytes, respectively,
were all up-regulated. Up-regulation of Sca1, Mac3,
and CD11b was also detected in BpV-treated MSCs
(Fig. 3C).
Figure 3. Effect of BpV on gene expression profile. Aa) RT-PCR analysis of expression of indicated markers of muscle cell
precursors, in both C2C12 and MSC cells, untreated or treated with BpV for 24 h. Ab) RT-PCR analysis of the expression of Pax7,
in both C2C12 and MSC cells, untreated or treated with BpV for 24 or 48 h. Proliferating cells (cultured in GM, P) were also
analyzed, as positive control. Ba) RT-PCR analysis of expression of indicated SP cells markers in untreated or BpV-treated C2C12
cells and MSCs. Bb) FACS profile on Hoechst 33342 staining of C2C12 cells and MSCs untreated or BpV-treated. Population of
cells located in the FACS profile as a SP is marked in each condition, and relative percentage is indicated. C) FACS-analysis of
the expression of indicated stem and hematopoietic markers in untreated (dotted line) and BpV-treated (solid line) C2C12 cells
and MSC, as indicated. Gray peak 	 control Ig.
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BpV treatment induces multilineage potentiality in
C2C12 cells
The gene expression profile acquired by the BpV-
treated cells prompted us to evaluate whether BpV-
treated cells may acquire multilineage potentiality. We
first assessed the ability to generate cells of different
hematopoietic lineages. To this aim, C2C12 cells were
cultured in the presence or in the absence of 10 M
BpV for 24 h and then shifted to myeloid colony assay
culture conditions, with or without lower BpV concen-
tration (2 M). After 5 days, although both untreated
and BpV-treated cells formed colonies at similar clon-
ing efficiency (2–3%), untreated cells formed clones of
adherent cells, while BpV-treated cells formed hemato-
poietic-like colonies (Fig. 4A). The hematopoietic-like
colonies were harvested to analyze cell morphology and
gene expression. As shown in Fig. 4A, many of the cells
acquired morphological features typical of myeloid
cells such as monocytes, macrophages or granulocytes.
Accordingly, RT-PCR analysis showed that harvested
BpV-treated cells expressed the granulocyte macro-
phage colony stimulating factor receptor (GM-CSFR)
and the interleukin-3 receptor (IL-3R), two genes
normally expressed in both hematopoietic stem cells
(HSCs) and common myeloid progenitors (CMPs; ref.
29; Fig. 4A). The potential of BpV pretreated cells to
generate cells of hematopoietic origin was further
confirmed by their ability to acquire an osteoclast-like
phenotype, when cultured for 5 days in DM supple-
mented with 100 nM 1,25(OH)2 vitamin D3 and 2 M
BpV. The acid phosphatase activity (TRAP) histochem-
ical assay showed that 20% of the BpV-treated cells
became TRAP positive (Fig. 4B). No TRAP-positive cells
were detectable in untreated controls. The acquisition
of an osteoclast-like phenotype on BpV treatment was
also confirmed by the induction of two osteoclast
transcripts, microphthalmia transcriptor factor (MFIT;
ref. 30) and matrix metalloproteinase (MMP9; ref. 31;
Fig. 4B).
We next verified whether BpV-treated cells were also
capable of differentiating into a cell lineage of mesen-
chimal origin, such as osteoblasts. C2C12 cells, as well
as MSCs, have long been known to have some multipo-
tentiality, including a BMP2 response that can induce
bone formation but only by treatment with very high
concentrations of BMP2 (100–300 ng/ml; ref. 32). We
tested whether BpV treatment may “prime” the cells to
be more responsive to signals generated by the environ-
ment, as BMP2 lower concentration. To this purpose,
untreated or BpV pretreated C2C12 cells, as above,
were cultured for 5 days in DM, supplemented with 50
Figure 4. Effect of BpV on cell lineage plasticity. A) phase contrast micrographs of the colonies obtained from untreated (a) and
BpV-treated (b) C2C12 cells cultured in Metho-Cult, with or without 2 M BpV; c– e, Giemsa staining of cells collected from
colonies, as in b. Bars 	 30 m. Upper right panel 	 RT-PCR analysis for the expression of the hemopoietic indicated markers
(GM-CSFR and IL3-R); B) histochemical assay for TRAP activity in untreated (a) and BpV-treated (b) C2C12 cells cultured, for
5 days, in DM containing 100 nM 1,25(OH)2 vitaminD3. Percentage of TRAP-positive cells is also shown. Bar 	 30 m. Right
panel 	 RT-PCR analysis for the expression of the osteoclast indicated markers (MFIT and MMP9). C) histochemical assay for
ALP activity in untreated (a) and BpV-treated (b) C2C12 cells cultured in DM containing 50 ng/ml BMP2. Bar 	 50 m.
Percentage of ALP-positive cells is also shown. Right panel 	 RT-PCR analysis for the expression of the osteoblast indicated
markers (OC: osteocalcine; Coll I: collagen I). -actin expression level was analyzed for each RNA sample to normalize the
reactions. Lane 1 	 untreated; lane 2 	 BpV-treated cells. D) immunofluorescence analysis for the expression of cardiac
troponin I (cTnI, red) in untreated (a) and BpV-treated (b) GFP-expressing C2C12 (green), cultured over a cardiomyocite
monolayer. Arrowhead 	 1 cell coexpressing cardiac troponin I and GFP within BpV-treated cells. Percentage of GFP/cTnI
coexpressing cells is also shown. Bar 	 10 m. Statistical analysis was conducted comparing at least three independent
experiments for each assay (**P0.005; ***P0.0005).
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ng/ml bone morphogenetic protein 2 (BMP2) with or
without 2 M BpV. The alkaline phosphatase activity
(ALP) hystochemical assay showed that cells treated
with only 50 ng/ml of BMP2 were negative for ALP
activity; however, 5% of the BpV-treated cells became
ALP positive (Fig. 4C). Osteoblast conversion of BpV-
treated cells was confirmed by the induction of the
transcripts for the osteoblast markers ALP, osteocalcin,
type I collagen as well as the Cbfa1 transcriptor factor,
which is considered the osteoblast master gene for its
essential role in osteogenesis and osteoblast differenti-
ation (33, 34; Fig. 4C).
Finally, we tested the ability of BpV-treated cells to
acquire a cardiomyocyte-like phenotype. To this pur-
pose, GFP-expressing C2C12 cells, untreated or BpV
pretreated, were seeded on a cardiomyocytes mono-
layer and cultured for additional 4 days, in DM with or
without 2 M BpV. As shown in Fig. 4D, none of the
BpV-untreated GFP-expressing cells coexpressed car-
diac tropononin I (cTnI, used as a cardiac marker), as
detected by immunofluorescence, whereas a small pro-
portion (0.5%) of BpV-treated GFP-expressing cells
coexpressed cTnI.
BpV-induced reprogramming of gene expression
requires NF-B activation
To understand the contribution of BpV-induced signal-
ing pathway(s) to the observed phenotype, we analyzed
AP1 and NF-B activity in BpV-treated muscle cells.
Both pathways are known to be induced by BpV (35,
36) and to be strongly down-regulated during myo-
genic differentiation (16–17).
As shown in Fig. 5A, BpV treatment induced a
transient activation of AP1 trascriptional activity, which
peaked at 6 h, with a concomitant activation of Ser-63
c-jun phosphorylation. Moreover, BpV induced a rapid
2- to 3-fold activation of NF-B-dependent transcrip-
tion, which peaked by 8–9 h and remained above the
basal activity throughout the 24 h of treatment. TNF-,
a well-known NF-B activator used as a control, induced
a similar 2- to 3-fold induction that decreased below the
basal activity within 15 h. Intriguingly, we did not
observe IB kinase (IKK) complex-dependent Ser-32-
IB phosphorylation nor IB degradation in re-
sponse to BpV treatment. By immunoprecipitation and
subsequent Western blot analysis, we demonstrated that
BpV induced both IB tyrosine phosphorylation and
p65 nuclear translocation, within 30 min of treatment
(Fig. 5A). Tyr42 phosphorylation of IB, followed or
not (depending on the cell system) by its proteolitic
degradation, has been identified recently as an “alter-
native” NF-B activation pathway induced by a number
of stimuli including the PTPase inhibitor pervanadate
(37, 38).
Next, we sought to verify whether BpV-induced acti-
vation of NF-B is required for the observed gene
expression. To this aim, C2C12 cells were transfected
with the p50SP expression vector, encoding the dom-
inant negative mutant form of the p50 NF-B subunit
(24). This mutant lacks the DNA-binding domain, but
it is able to form both homo- and hetero-dimers with
the other members of the family (p65 and RelB, as the
major subunits expressed in C2C12 cells; ref. 39), thus
functioning as a super-repressor for NF-B activity. A
GFP expression vector was also cotransfected (at a 5:1
M ratio p50SP:GFP). The cells were transferred in DM
with or without 10 M BpV. After 24 h, the cells were
FACS analyzed for the expression of c-kit and Mac3,
used as molecular markers of BpV-induced gene ex-
Figure 5. A) Effect of BpV on NF-B and AP1 transcriptional
activities. Luciferase activity assayed at different periods of
time in AP1- (a) or NF-B-Luc (c) transfected C2C12 cells
treated or not with 10 M BpV or 5 ng/ml TNF-. Luc activity
was expressed as fold induction over untreated cells. Western
blot analysis of protein extracts prepared from cells treated or
not with BpV for different period of times, as indicated, and
probed with the antic-jun or with the anti-Ph-Ser-63 c-jun in
(b). In d, extracts were immunoprecipitated using anti-IkB
antibody and blots were reacted with anti-IB or with
anti-Ph-Ser-32 IB, as well as with the anti-Ph-Tyr antibody.
From parallel cultures, nuclear fractions were prepared and
blot was reacted with the antip65 antibody. B) Effect of
p50SP expression on BpV-induced gene expression. FACS
analysis of expression of c-kit and Mac3, in C2C12 cells
cotransfected with the p50SP and the GFP expression
vectors, and treated (BpV) or not treated (Ctr) with BpV. Two
populations of cells were delimitated in FACS profile: GFP-
negative (GFP) and GFP-expressing cells (GFP
). BpV-
induced expression of c-kit or Mac3 was reported as fold
induction as compared to Ctr cells for each population (right
histograms), as a mean (sd) from 3 independent experi-
ments (*P0.03).
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pression changes. The expression of the exogenous
p50SP was assessed in parallel cultures by Western
blot analysis, as its ability to reduce NF-B-dependent
gene activation by gene reporter assay (see Supplemen-
tal Fig. S1). The results showed that the BpV-induced
2-fold c-kit expression in GFP cells was significantly
reduced in GFP
 p50-transfected cells (Fig. 5B);
similarly, p50SP mutant expression prevented the
3-fold Mac3 induction by BpV in the GFP
 cell popu-
lation (Fig. 5B). Parallel cultures were analyzed for
morphology and a significant 40% reduction in cells
acquiring round shape morphology was observed (not
shown).
BpV-treated muscle cells acquire the phenotype of a
circulating progenitor
Finally, we sought to verify whether the gene expression
profile and the multipotentiality of BpV-treated cells
might also be associated with the acquisition of the
phenotype of circulating progenitor, which could be
delivered systemically and colonize different tissues. To
this purpose, 5  105 GFP-expressing C2C12 cells,
untreated or treated with BpV for 24 h, were injected
into the femoralis artery of SG/ mice (3). These
mice represent a model for muscular dystrophy, in
which degenerating muscle fibers are continuously
replaced by muscle cell precursors. Three days after
intra-arterial transplantation, very few untreated GFP-
positive mono-nucleated cells were observed, restricted
within very damaged areas of the skeletal muscle tissue
(data not shown). By contrast, when BpV-treated cells
were transplanted, a large number of clustered GFP-
expressing mononucleated cells were observed, most of
which expressed c-Kit (Fig. 6A–C) but not MyoD (not
shown). Although with variability among different mi-
croscopic fields, hundreds of donor cells could be
detected. By day 5, an average of five to six GFP-positive
mono-nucleated cells/micro- field were observed,
spread throughout the muscle, mostly in the interstitial
space (Fig. 6D, G). By day 7, some of these cells
(5–10%) could be detected that now expressed MyoD,
indicating the activation of a myogenic differentiation
program (Fig. 6E). By day 21, many fibers (8217/
cross sectional area) of the transplanted tibialis anterior
(TA) expressed SG (an example is shown in Fig. 6F).
Quantitative RT-PCR analysis showed that a significant
recover of SG expression was detectable in the intra-
arterially transplanted TA (Fig. 6H). Untreated C2C12
cells did not give rise to SG positive fibers when
transplanted intra-arterially (not shown). These results
demonstrate that BpV treatment significantly enhances
the ability of C2C12 cells to circulate, to cross the vessel
wall, and consequently, to contribute to muscle regen-
eration.
DISCUSSION
In this study, we demonstrated that myogenic cells
treated with the PTP inhibitor BpV acquire functional
plasticity with the ability, when cultured in the appro-
priate conditions, to commit toward phenotypes be-
longing to distinct lineages; to colonize, via arterial
circulation, skeletal muscle; and, finally, to contribute
to muscle regeneration.
The feasibility of reprogramming gene expression
and reverting already committed cells into a pluripo-
tent state by the ectopic expression of specific genes is
supported by a number of observations (12, 14, 15, 40).
Cell fate can be changed upon exposure to nuclear and
cytoplasmic extracts from cells of different origin (41,
42) or by cell fusion (43). Certain extracellular signals
also exert similar effects: FGF2 induces oligodendro-
cyte precursor cells to revert to multipotential neural
stem cells (44), whereas the SP subset within C2C12
muscle cells is expanded upon exposure to FGF6 (45).
Differently from models that require the ectopic ex-
pression of a given gene, the use of cell surface receptor
ligands, or pharmacological compounds can induce a
reversible blockade of the differentiation program,
thus allowing treated cells to redifferentiate when
placed in the right microenvironment.
We show here that BpV-treated myoblasts acquire a
round shape morphology and an anchorage-indepen-
dent phenotype, inhibiting myogenic differentiation.
More importantly, BpV-dependent inhibition of differ-
entiation is reversible, as myoblasts (both C2C12 and
MSC cells) recover their myogenic potential on re-
moval of the drug. BpV-treated cells do not arrest, nor
differentiate, but continue to divide, though cultured
in DM. Importantly, longer exposure to 10 M BpV
(48–72 h) results, in agreement with its reported
anti-neoplastic activity (20), in cell death. BpV effects
on muscle cells proliferation and differentiation can be
explained by its ability to prevent the down-regulation
of NF-B and AP1 transcriptional activity. Accordingly,
cyclin D1 expression, the transcription of which is
known to be regulated by NF-B in proliferating myo-
blasts (17), is up-regulated in BpV-treated myoblasts
cultured in DM. TNF-, which interferes with NF-B
and AP1 down-regulation, also blocks myogenic differ-
entiation, but its effect is not reversible, possibly due to
the concomitant degradation of myogenic transcripts
(18). In addition, BpV-dependent NF-B activation,
differently from TNF-, involves an alternative activa-
tion pathway that is mediated by Tyr42-IB phosphor-
ylation and NF-B subunits nuclear translocation with-
out IB degradation. Further experiments will be
needed to precisely define the molecular mechanisms
underlying the selectivity of BpV activities in myoblasts
and the relative contribution of the BpV-induced sig-
naling pathways. However, according to the results
obtained with the p50SP dominant negative mutant,
we provide evidence that NF-B signaling and transcrip-
tion activity are indeed required for BpV-dependent
reprogramming of gene expression.
Our results also show that BpV dramatically modifies
muscle cells gene expression profile: MRFs are down-
regulated, whereas Pax7 down-regulation is delayed as
the expression of markers defining muscle precursor
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cells, such as, Pax-3 and c-met. Moreover, BpV treat-
ment induces the expression of markers characteristic
of adult mesenchymal or hematopoietic stem cells,
such as CD34, Sca-1, and c-kit, as well as of hematopoi-
etic lineages (CD45, CD11b, Mac-3, Gr-1, and Ter-119).
Importantly, BpV treatment also induces the expres-
sion of a complete set of the ABC transporters and the
expansion of the SP in both C2C12 cells and MSC.
Whether similar gene expression profile is activated in
all the exposed cells or whether different cell subpopu-
lations arise upon BpV treatment, expressing different
sets of genes, is not yet clear. Anchorage-independency
appears not to reflect a cell selection, in terms of both
gene expression and differentiation potential (not
shown). However, altogether, the observed gene ex-
pression profile suggests that BpV induces a broad
reprogramming of gene expression.
Accordingly, BpV-treated C2C12 cells greatly expand
their plasticity and acquire the ability to differentiate
along multiple lineages (hematopoietic/myeloid, in-
cluding osteoclast, and cardiomyocyte). Indeed, BpV
exposure lowers the BMP2 concentration required for
C2C12 cells conversion into osteoblast (24, 35). Al-
though BpV-promoted plasticity may not have actual
applications per se, it strongly supports the conclusion
that BpV imposes to the exposed cells the phenotype of
precursor cells and “primes” the cells to be more
responsive to signals generated by the environment.
Figure 6. Intra-arterial transplantation of BpV-treated GFP-C2C12 cells in SG /mice. A–C) Immunofluorescence analysis of
TA muscle cryo-sections from SG/mice, transplanted, via femoral artery delivery, with BpV-treated GFP-C2C12 cells, 3 days
after the injection. GFP
 cells are stained in green by an anti-GFP antibody (A) and c-kit expressing cells in red by an anti-cKit
antibody (B); merged image is shown in C. D) Merged immunofluorescence image of a cryo-section of a similarly transplanted
TA muscle, 5 days after transplantation. GFP
 cells are stained in green and laminin in red by the anti-laminin antibody. Higher
magnification is shown in inset. Number of GFP
 cells/micro-field (at least 20 randomized microfield/sample) counted in
muscles transplanted with either untreated (CTR) or BpV-treated (BpV) cells is reported in G, as mean (se) from 3
independent experiments (***P0.001). E) Merged immunofluorescence image of a cryo-section of a similarly transplanted TA
muscle, 7 days after transplantation. GFP
 cells are stained in green and MyoD expressing cells in red. Arrow indicates two
GFP
/MyoD
 cell whereas arrowhead indicates a resident GFP/MyoD
 cell. F) Immunofluorescence analysis of similarly
transplanted TA muscle, 21 days after transplantation. Anti-SG antibody stains positive fibers in red. GFP was no longer
detected at this stage probably due to dilution of the protein after fusion. In all sections, nuclei are stained in blue by Hoechst.
(H) TA muscles from -SG/ mice (n	3), injected via femoral artery with BpV-treated GFP-C2C12 cells (BpV), were pooled
21 days after injection and subjected to real-time PCR for the presence of -SG. WT and -SG null (KO) muscles are also shown
for comparison (***P0.001, as compared to KO).
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The ability to circulate, to migrate across the endo-
thelium, and to colonize different tissues (i.e., the
acquisition of a circulating progenitor phenotype)
would certainly represent an highly desirable property
in the perspective of developing innovative cell therapy
strategies.
The results reported in this study demonstrate that,
when injected systemically, BpV-treated C2C12 cells,
are able to migrate outside the vessels in the presence
of inflammation, as in the case of dystrophic muscle; to
reach muscle tissue, with a much higher efficiency than
untreated cells; and, more importantly, to contribute to
muscle repair. Thus, BpV imposes to C2C12 cells the
phenotype of circulating precursors, increasing their
homing toward the dystrophic muscle, while maintain-
ing their myogenic potential, because of the reversibil-
ity of the effect. It is noteworthy that the reversion to
the myogenic phenotype of BpV-treated cells delivered
by intra-arterial injections occurs much slower in vivo
than in vitro, as demonstrated by the persistent expres-
sion of c-Kit and the late appearance of MyoD. Never-
theless, after 21 days many injected cells had produced
SG-expressing fibers.
The mechanism used by transplanted cells to reach
muscle tissues is not clear at the moment. An attractive
hypothesis would be that BpV treatment induces in-
flammatory cytokines receptors expression, the tran-
scription of which is regulated by NF-B signaling in
many cases, allowing circulating myogenic cells to re-
spond to signals from the inflammatory environment of
the dystrophic muscle. Sensitivity to such signals may
thus improve homing, but, on the other hand, it may
prevent myogenic differentiation, thus explaining the
observed in vivo delay in the activation of the myogenic
phenotype, as compared to the in vitro results.
In conclusion, the results reported in this study
suggest that BpV treatment may represent a valuable
approach to generate circulating precursors from com-
mitted cells, suitable for gene-cell therapy applications,
as well as to study the molecular mechanism leading to
genome reprogramming and “stem-ness.”
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